Mastitis Market Trends, Analysis, Key Players, Outlook, Report, Forecast 2025-2032

Mastitis Market Set to Reach USD 2.16 Billion by 2030, Driven by Rising Veterinary Awareness and Dairy Industry Expansion

Market Estimation, Growth Drivers & Opportunities
The global mastitis market, valued at USD 1.42 billion in 2023, is expected to reach USD 2.16 billion by 2030, growing at a CAGR of 6.2% during the forecast period. Mastitis—an inflammation of the mammary gland in dairy animals—is one of the most economically damaging diseases in the dairy industry, affecting milk quality and yield.

Request Free Sample Report:https://www.stellarmr.com/report/req_sample/Mastitis-Market/2101

The growth of the mastitis market is primarily fueled by the increasing global dairy production, a rising awareness of animal health, and expanding access to veterinary care. As milk demand rises globally, so does the focus on herd health and productivity. Subclinical mastitis—hard to detect without diagnostic tools—has driven demand for effective screening and early-treatment solutions.

Opportunities are abundant in developing nations where modern livestock management is gaining traction. Further, advancements in intramammary antibiotics, development of teat sealants, and innovations in rapid diagnostic kits present immense growth potential. With the One Health approach gaining momentum, investments in animal health are now being directly linked to food safety and public health outcomes, offering more policy-level support for market expansion.

United States Market: 2024 Trends and Investments
The U.S. mastitis market has seen significant developments in 2024. Large-scale dairy farms are increasingly adopting precision livestock technologies, including mastitis detection systems using infrared thermography, machine learning, and automated milking systems equipped with biosensors. As of 2024, there’s a growing shift toward preventative care, with U.S. veterinary service providers emphasizing dry cow therapy and selective antibiotic use, in compliance with FDA guidelines.

Recent investment trends show a rise in funding for biotech companies working on mastitis vaccines and non-antibiotic treatments. The USDA has also increased grants supporting antimicrobial resistance research in livestock diseases, including mastitis. This aligns with federal efforts to improve milk quality and reduce antibiotic residues in the food chain.

Market Segmentation: Leading Segments by Share
Among the various treatment types, Antibiotics dominate the mastitis market with the largest share in 2023, accounting for over 50% of the global revenue. Antibiotic therapy remains the primary treatment for both clinical and subclinical mastitis, particularly in high-producing dairy regions. However, regulatory and consumer pushback against overuse is shifting focus toward selective dry cow therapy and the integration of diagnostic tools.

By route of administration, Intramammary treatment leads the market. It offers targeted delivery of antibiotics directly into the affected udder quarters, ensuring faster recovery with lower systemic exposure. This method has become a standard across developed dairy industries.

In terms of animal type, Dairy Cattle represent the largest segment. Their economic value, combined with susceptibility to mastitis due to intensive milking, puts them at the center of treatment demand. Other ruminants like goats and sheep also contribute but form a smaller market share.

Competitive Analysis: Top 5 Market Leaders and Innovations
The mastitis market is moderately consolidated, with a few major players commanding substantial market share. The top five companies contributing significantly to the global market include:

Boehringer Ingelheim Animal Health – A leader in animal health, Boehringer has recently enhanced its mastitis portfolio through new generation intramammary antibiotics with reduced withdrawal times. The company also focuses on integrated herd health solutions combining diagnostics, treatment, and monitoring.

Zoetis Inc. – Zoetis continues to lead innovation by investing in real-time monitoring systems for udder health. The company has introduced cloud-based tools for mastitis tracking and launched research collaborations targeting antibiotic-free mastitis therapies.

Bimeda Animal Health – With a strong presence in emerging markets, Bimeda is focusing on broad-spectrum antibiotics and injectable therapies. Recent policy shifts toward residue-free milk in Asia and Africa have created expansion opportunities for their portfolio.

Ceva Santé Animale – Known for its focus on reproductive and udder health, Ceva has developed comprehensive mastitis control programs and invested in on-farm diagnostic test kits, helping farmers detect subclinical cases early.

Elanco Animal Health – Elanco continues to expand its R&D in immunotherapy for bovine mastitis, aiming to reduce antibiotic dependency. In 2024, the company announced funding toward alternative therapies, including bacteriophage treatments and vaccine prototypes.

These companies are driving market growth through innovation, education programs, and strategic partnerships with dairy cooperatives, enhancing disease management practices globally.

Regional Analysis: Market Dynamics in Key Countries

United States: North America holds a significant market share, led by the U.S., which benefits from large-scale dairy farms and widespread veterinary service access. Strong regulatory frameworks, such as the FDA’s Guidance for Industry #263, promote responsible antibiotic use. Federal subsidies and tech adoption in smart farming further support growth.

United Kingdom: The UK’s mastitis market is advanced due to its focus on dairy sustainability and herd welfare. The British government’s push for antibiotic stewardship in agriculture has driven demand for diagnostics and non-antibiotic treatments. Research grants through organizations like Innovate UK are supporting biosensor-based solutions.

Germany: As one of Europe’s dairy powerhouses, Germany has seen growth in precision dairy farming. The German Federal Ministry of Food and Agriculture has endorsed mastitis control programs with financial support for early diagnostic tech and herd health management.

France: France's mastitis market benefits from its diverse dairy landscape and premium cheese production, which demands high milk quality. Government-backed herd health programs and cooperatives have pushed for selective treatment protocols to preserve milk purity.

Japan: Japan’s highly organized dairy sector has adopted robotic milking systems that integrate mastitis detection. Supported by government initiatives for agricultural modernization and herd productivity, Japan is investing in veterinary R&D focused on subclinical mastitis.

China: With rapid growth in its dairy sector, China faces rising mastitis cases due to intensive milking and lack of consistent veterinary coverage in rural areas. The government has initiated subsidies to improve livestock health services and promote domestic production of veterinary pharmaceuticals.

Conclusion: Future Outlook and Growth Opportunities
The mastitis market is poised for steady expansion as dairy production scales up globally. Antibiotics remain a dominant treatment segment, but the tide is gradually shifting toward sustainable, preventative, and precision-based solutions. The rise of digital livestock monitoring, selective therapy, and on-farm diagnostics is redefining mastitis management.

Emerging markets offer untapped potential where veterinary infrastructure is improving. Additionally, government policies worldwide now favor antimicrobial stewardship, creating a pathway for vaccine development, immunotherapies, and alternative treatments to flourish.

In conclusion, the mastitis market’s future lies in an integrated approach—combining smart diagnostics, responsible antibiotic use, farmer education, and preventive care. Companies that align their strategies with evolving regulations and invest in technology-driven solutions will be best positioned to lead this market in the years ahead.

About us

Phase 3,Navale IT Zone, S.No. 51/2A/2,

Office No. 202, 2nd floor,

Near, Navale Brg,Narhe,

Pune, Maharashtra 411041

+91 9607365656

sales@stellarmr.com